Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07718815

HLA B Leader in Patients With Psoriatic Arthritis

Psoriatic arthritis (PsA), a chronic immune-mediated heterogeneous inflammatory disease characterized by musculoskeletal inflammation (arthritis, enthesitis, spondylitis and dactylitis), usually occurs in patients with psoriasis. The spondyloarthritides (SPs) (of which psoriasis is one) are a group of inflammatory diseases that share an association with the HLA-B27 MHC class I molecule.

Given this association, these diseases are classically regarded as disorders of adaptive immunity.

In bone marrow donation, HLA-B exon 1 dimorphism (HLAB leader) is associated with risk of graft- versus-host disease, relapse and overall survival after unrelated hematopoietic cell transplantation (UHCT), haploidentical UHCT and cord transplantation. In the literature, there are no studies suggesting the involvement of the HLA B leader gene in MS and RPs. The main aim of this study is to compare the presence of the HLA B leader gene between a group of patients with psoriatic arthritis and a healthy group without inflammatory disease.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Psoriatic Arthritis Arthritis Arthritis, Psoriatic Bone Diseases HLA B27 HLA b Leader Joint Diseases Musculoskeletal Diseases Psoriasis Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases Spinal Diseases Spondylarthritis Spondylarthropathies Spondylitis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU Amiens Picardie

Amiens, Picardie, 80054, France

Location status: Recruiting

Location contact

Vincent GOEB, Pr

CONTACT

[email protected]

+33322668259

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • For the "Patient" group:
  • Patient over 18 years of age
  • Patient affiliated to a social security scheme
  • Patient with psoriatic arthritis according to the CASPAR 2006 classification, followed at the CHU Amiens-Picardie.
  • For the "control" group:
  • Individuals over 18 years of age
  • Individual affiliated to a social security scheme
  • Individual having agreed to participate in the study
  • Individuals with no inflammatory or autoimmune diseases

Exclusion criteria

  • Patient or control not understanding French
  • Patient not included in the Amiens Picardie University Hospital's "Psoriatic Rheumatism" cohort, or control not included in the Amiens Picardie University Hospital's bone marrow donor cohort.
  • Patient or control objecting to participation in the study

Treatment and study plan

blood test

Biological

Addition of an extra tube for blood tests (a single tube for genetic research), enabling phenotyping of the HLA B27 and HLA B leader genes.

Primary outcomes

  1. prevalence of HLA B leader in both groups

    Time frame: 1 year

    prevalence of HLA B leader in patients with psoriatic rheumatism compared to the healthy group by autoimmune disease

Secondary outcomes

  1. Prevalence of HLAB27 gene in both groups

    Time frame: 1 year

    Prevalence of HLAB27 gene in patients with psoriatic rheumatism compared to the healthy group free from autoimmune disease

  2. prevalence of the HLAB27/ HLA b Leader gene in different forms of psoriatic rheumatism patient group

    Time frame: 1 year

    prevalence of the HLAB27/ HLA b Leader gene in different forms of psoriatic rheumatism in patients with different disease conditions

Study contacts

Contact information is provided by the study sponsor or research team.

Vincent Goeb, Pr

CONTACT

[email protected]

33+3.22.08.83.71

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire, Amiens

Other

Registry information

Acronym: HLABLRP

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jul 22, 2026
Registry last updated
Jul 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.